Soleno Therapeutics Inc
NASDAQ:SLNO 4:00:00 PM EDT
| Market Cap (Intraday) | 4.34B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 80.57 |
| 10-Day MA | $83.01 |
| 50-Day MA | $77.13 |
| 200-Day MA | $58.20 |
Soleno Therapeutics Inc Stock, NASDAQ:SLNO
100 Marine Parkway, Suite 400, Redwood City, California 94065
United States of America
Phone: +1.650.213.8444
Number of Employees: 92
Description
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.